Fused tricyclic imidazole derivatives as modulators of TNF activity

US10087179B2 · kind B2 · utility

Assignee

• UCB BIOPHARMA SRL · BE

Inventors

• Rikki Peter Alexander · Slough, GB
• Gareth Neil Brace · Abingdon, GB
• Julien Alistair Brown · Slough, GB
• Mark Daniel Calmiano · Slough, GB
• Prafulkumar Tulshibhai Chovatia · Abingdon, GB
• Michael Deligny · Brussels, BE
• Ellen Olivia Gallimore · Slough, GB
• Jag Paul Heer · Brussels, BE
• Victoria Elizabeth Jackson · Slough, GB
• Boris Kroeplien · Slough, GB
• Malcolm MacCoss · Freehold, US
• Joanna Rachel Quincey · Slough, GB
• Yogesh Anil Sabnis · Sandwich, GB
• Dominique Swinnen · Braine-l'Alleud, BE
• Zhaoning Zhu · Plainsboro, US
• Uwe Heinelt · Wiesbaden, DE
• Volkmar Wehner · Bischofsheim a.d.Rhön, DE

Key dates

• Filing date: Dec 8, 2014
• Grant date: Oct 2, 2018
• Expiry date: Dec 8, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A series of fused tricyclic imidazole derivatives, in particular dihydro-1H-cyclopenta[4,5]imidazo[1,2-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.